Current CML therapy: progress and dilemma
Rarely has progress in treatment of leukemia been as dramatic and convincing as with the BCR-ABL tyrosine kinase inhibitor imatinib.1 Imatinib induces remissions of CML as fast as hydroxyurea, achieves rates of cytogenetic remissions that by far exceed those induced by interferon α and has a toxicit...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 May 2003
|
| In: |
Leukemia
Year: 2003, Volume: 17, Issue: 6, Pages: 1010-1012 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2402951 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2402951 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2402951 
|
| Author Notes: | R. Hehlmann |
| Summary: | Rarely has progress in treatment of leukemia been as dramatic and convincing as with the BCR-ABL tyrosine kinase inhibitor imatinib.1 Imatinib induces remissions of CML as fast as hydroxyurea, achieves rates of cytogenetic remissions that by far exceed those induced by interferon α and has a toxicity profile as favourable as that of hydroxyurea and much superior to that of interferon α.2 In addition, the causal approach of this new drug, which may well serve as a model for new treatment modalities in other neoplasias is reassuring. |
|---|---|
| Item Description: | Gesehen am 13.05.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2402951 |